Journal
LANCET
Volume 376, Issue 9743, Pages 826-834Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(10)61380-3
Keywords
-
Categories
Funding
- Novartis
- AstraZeneca
- GlaxoSmithKline
- MedImmune
- Ception
- MAP
- Gray Consulting
- Smith Research
- Quintiles
- Scienomics
- Genentech
- Pharmaxis
- Merck Inc
- NIAID/NIH [HHSN272200900052C, R01 HL097134]
- NIH [R01 HL097134, P01 HL070831, U10 HL064305, U10 HL074212, U10 HL098090, U19 AI070503]
Ask authors/readers for more resources
Viral respiratory tract infections are common and usually selflimited illnesses. For patients at risk of asthma, or with existing asthma, viral respiratory tract infections can have a profound effect on the expression of disease or loss of control. New evidence has shown that wheezing episodes early in life due to human rhinoviruses are a major risk factor for the later diagnosis of asthma at age 6 years. For those with existing asthma, exacerbations are a major cause of morbidity, can need acute care, and can, albeit rarely, result in death. Viral respiratory tract infections, predominantly those caused by human rhinoviruses, are associated with asthma exacerbations. There is also evidence that deficiencies in antiviral activity and the integrity of the airway epithelial barrier could make individuals with asthma more likely to have severe viral respiratory infections of the lower airway, and thus increase the risk of exacerbation. In view of the effect of respiratory viruses on many aspects of asthma, efforts to understand the mechanisms and risk factors by which these airway infections cause changes in airway pathophysiology are a first step towards improved treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available